Japanese Encephalitis - Pipeline Review, H2 2015

Publisher Name :
Date: 09-Dec-2015
No. of pages: 47
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's, ‘Japanese Encephalitis - Pipeline Review, H2 2015', provides an overview of the Japanese Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Japanese Encephalitis and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Japanese Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Japanese Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Japanese Encephalitis - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Japanese Encephalitis Overview 7
Therapeutics Development 8
Pipeline Products for Japanese Encephalitis - Overview 8
Pipeline Products for Japanese Encephalitis - Comparative Analysis 9
Japanese Encephalitis - Therapeutics under Development by Companies 10
Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 11
Japanese Encephalitis - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Japanese Encephalitis - Products under Development by Companies 15
Japanese Encephalitis - Products under Investigation by Universities/Institutes 16
Japanese Encephalitis - Companies Involved in Therapeutics Development 17
Indian Immunologicals Limited 17
Panacea Biotec Limited 18
Sanofi 19
Vaxine Pty Ltd 20
Zydus Cadila Healthcare Limited 21
Japanese Encephalitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
encephalitis vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FDX-000 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Japanese encephalitis vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Japanese encephalitis vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Japanese encephalitis vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Japanese encephalitis vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Japanese encephalitis vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Japanese encephalitis vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Japanese encephalitis vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Japanese encephalitis vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Japanese Encephalitis - Recent Pipeline Updates 42
Japanese Encephalitis - Dormant Projects 43
Japanese Encephalitis - Discontinued Products 44
Japanese Encephalitis - Product Development Milestones 45
Featured News & Press Releases 45
Dec 10, 2012: Sanofi Pasteur Launches Imojev First Single-dose Vaccine Against Japanese Encephalitis In Australia 45
Jun 29, 2007: Discontinuation of Japanese encephalitis vaccine 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for Japanese Encephalitis, H2 2015 8
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Comparative Analysis by Unknown Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H2 2015 17
Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H2 2015 18
Japanese Encephalitis - Pipeline by Sanofi, H2 2015 19
Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H2 2015 20
Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Japanese Encephalitis Therapeutics - Recent Pipeline Updates, H2 2015 42
Japanese Encephalitis - Dormant Projects, H2 2015 43
Japanese Encephalitis - Discontinued Products, H2 2015 44

List of Figures

Number of Products under Development for Japanese Encephalitis, H2 2015 8
Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Routes of Administration, H2 2015 25
Number of Products by Stage and Routes of Administration, H2 2015 25
Number of Products by Molecule Types, H2 2015 27
Number of Products by Stage and Molecule Types, H2 2015 27
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 35
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and som......
  • Behcet Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 65
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, h......
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 64
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headach......
  • Post Menopausal Osteoporosis - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 73
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone stru......
  • Pompe Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Pipeline Review, H1 2017, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up ......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wri......
  • LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017
    Published: 12-May-2017        Price: US 1250 Onwards        Pages: 57
    DelveInsight's, "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. This report provides information on the therapeutic development based on the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists dealing with all the pipeline......
  • Radiation Toxicity - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 202
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal ......
  • Guillain-Barre Syndrome - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrica......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs